Business

Gilead to license generic version of Sovaldi

By Tom Murphy
Published September 15, 2014 2:04pm ET
Add Washington Examiner on Google
Gilead to license generic version of Sovaldi
U.S. deterrence policy has generated plenty of criticism from Capitol Hill. But that has been aimed at the administration's supposedly narrow view of what constitutes an attack and unwillingness to spell out likely responses. | kaptnali

Gilead Sciences has reached a deal with several generic drugmakers to produce a cheaper version of its popular, $1,000-per-pill hepatitis C drug Sovaldi for use in developing countries.

Gilead said Monday that the India-based companies will make a generic version of Sovaldi, also known as sofosbuvir, and another investigational drug for distribution in 91 countries.

Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.